JP2024515307A - 修飾ポリペプチド及びその使用 - Google Patents

修飾ポリペプチド及びその使用 Download PDF

Info

Publication number
JP2024515307A
JP2024515307A JP2023564671A JP2023564671A JP2024515307A JP 2024515307 A JP2024515307 A JP 2024515307A JP 2023564671 A JP2023564671 A JP 2023564671A JP 2023564671 A JP2023564671 A JP 2023564671A JP 2024515307 A JP2024515307 A JP 2024515307A
Authority
JP
Japan
Prior art keywords
cyclin
polypeptide
seq
nucleic acid
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515307A5 (https=
Inventor
チョン，ロジャー
リー，アルバート
レイナー，ステファニー
モルシュ，マルコ
ルー，ルアン
Original Assignee
マッコーリー ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901193A external-priority patent/AU2021901193A0/en
Application filed by マッコーリー ユニバーシティー filed Critical マッコーリー ユニバーシティー
Publication of JP2024515307A publication Critical patent/JP2024515307A/ja
Publication of JP2024515307A5 publication Critical patent/JP2024515307A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/095—Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023564671A 2021-04-22 2022-04-22 修飾ポリペプチド及びその使用 Pending JP2024515307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021901193 2021-04-22
AU2021901193A AU2021901193A0 (en) 2021-04-22 Modified polypeptides and uses thereof
PCT/AU2022/050366 WO2022221922A1 (en) 2021-04-22 2022-04-22 Modified polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2024515307A true JP2024515307A (ja) 2024-04-08
JP2024515307A5 JP2024515307A5 (https=) 2025-04-23

Family

ID=83723498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564671A Pending JP2024515307A (ja) 2021-04-22 2022-04-22 修飾ポリペプチド及びその使用

Country Status (7)

Country Link
US (1) US20240199713A1 (https=)
EP (1) EP4326340A4 (https=)
JP (1) JP2024515307A (https=)
CN (1) CN117241838A (https=)
AU (1) AU2022261654A1 (https=)
CA (1) CA3215808A1 (https=)
WO (1) WO2022221922A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007194A1 (en) * 2023-07-05 2025-01-09 Macquarie University Modulation of gene expression
WO2025081231A1 (en) * 2023-10-16 2025-04-24 Infensa Bioscience Pty Ltd Inhibitors and uses therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500174A (ja) * 2016-11-07 2020-01-09 マックォーリー・ユニバーシティ タンパク質蓄積の調節及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126918A1 (en) * 2019-01-14 2020-07-23 President And Fellows Of Harvard College Methods and compositions for restoring stmn2 levels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500174A (ja) * 2016-11-07 2020-01-09 マックォーリー・ユニバーシティ タンパク質蓄積の調節及びその使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J BIOL CHEM, vol. 277 (38), JPN6026012391, 2002, pages 35140 - 35149, ISSN: 0005829037 *
KIMBERLEY DUNCAN, CHARACTERISING THE FUNCTIONAL DOMAINS OF THE CANDIDATE ALS PROTEIN, CYCLIN F, JPN6026012390, 2016, ISSN: 0005829035 *
NAT COMMUN, vol. 6, 5800, JPN6026012394, 2015, pages 1 - 11, ISSN: 0005829038 *
NAT COMMUN, vol. 7, 11253, JPN6026012392, 2016, pages 1 - 8, ISSN: 0005829039 *
NATURE, vol. 466, JPN6026012393, 2010, pages 138 - 142, ISSN: 0005829036 *

Also Published As

Publication number Publication date
US20240199713A1 (en) 2024-06-20
AU2022261654A1 (en) 2023-11-09
CN117241838A (zh) 2023-12-15
AU2022261654A9 (en) 2023-11-16
WO2022221922A1 (en) 2022-10-27
CA3215808A1 (en) 2022-10-27
EP4326340A4 (en) 2025-04-16
EP4326340A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7221275B2 (ja) Ａａｖを送達するための組成物および方法
US20220333131A1 (en) Modulatory polynucleotides
US10301366B2 (en) Compositions and methods for treatment of disorders related to CEP290
EP2844302B1 (en) Viral vectors for the treatment of retinal dystrophy
AU2008216018B2 (en) Mitochondrial nucleic acid delivery systems
JP2019533428A (ja) 標的遺伝子導入のための方法および組成物
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
US20220362404A1 (en) Modulation of cellular viability
JP2024515307A (ja) 修飾ポリペプチド及びその使用
WO2021252989A2 (en) Aav-mediated gene transfer for retinopathy
WO2010037143A1 (en) Vectors and methods of treating brain seizures
AU2019328337B2 (en) Methods of treating or preventing amyotrophic lateral sclerosis
US20240392279A1 (en) Modified protein disulfide isomerase and uses thereof
US20240307557A1 (en) Therapeutic gene silencing with crispr-cas13
WO2025007194A1 (en) Modulation of gene expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331